Skip to main content
MARKSANS · Health Care · 2026-08-07

Marksans Pharma Ltd

5.8★ FairSolid +6.1Stage 2 · wk 11In scan: Prop Scan · Pullback HunterMARKET: BULL TOPPING · 2026-08-07
₹273.9
+1.84% today
₹12,410 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Visit company website →
P/E (TTM)
27.0
Forward 19.3
Earnings Growth (YoY)
+8.2%
Revenue +10.6%
Dividend Yield
0.36%
P/B 4.2
vs 52W High
-1.2%
₹156.9 lo₹277.3 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
35.7%
200 DMA: ₹201.8 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.41x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -0.6% vs MA50 +9.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #37 of 79 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #27 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-15 → 2026-08-07
S2 22w
S2 16w
S2 39w
S4 15w
S4 14w
2023-05-152026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 22w → S3 4w → S2 16w → S3 7w → S2 39w → S3 7w → S4 11w → S1 11w → S4 15w → S1 8w → S4 14w → S1 4w → S2 11w current
Total tracked: 168 weeks across 13 stage runs.
1M
-1.2%
3M
+38.5%
6M
+66.4%
YTD
+54.0%
1Y
+16.3%
Scan Membership
Prop Scan
Latest: 2026-08-07
Pullback Hunter
Latest: 2026-08-06
60 appearances in last 60 days. First seen: 2026-06-10.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 11 · Vol x
2026-08-06S2
Wk 11 · Vol x
2026-08-05S2
Wk 11 · Vol x
2026-08-04S2
Wk 11 · Vol x
2026-08-03S2
Wk 11 · Vol x
2026-07-31S2
Wk 10 · Vol x
2026-07-30S2
Wk 10 · Vol x
2026-07-29S2
Wk 10 · Vol x
2026-07-28S2
Wk 10 · Vol x
2026-07-27S2
Wk 10 · Vol x
2026-07-24S2
Wk 9 · Vol x
2026-07-23S2
Wk 9 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹258.5
200 DMA
₹201.8
52W High
₹277.3
52W Low
₹156.9
5D Low
₹262.3
Resistance levels (recent highs)
20d High
₹275.8
60d High
₹277.3
120d High
₹277.3
250d High
₹277.3
Next resistance
+0.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.